<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-four patients with high risk primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and an excess of marrow blasts were treated with a combination of low-dose Ara-C, <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> and <z:chebi fb="0" ids="28940">vitamin D3</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Morphological subtypes were <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 16, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 20 and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in eight patients </plain></SENT>
<SENT sid="2" pm="."><plain>The therapy was continued in responders until relapse or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The results were compared to those of a matched control of 44 patients given a supportive therapy only </plain></SENT>
<SENT sid="4" pm="."><plain>In the treated group the overall response rate was 50% (75% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 50% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and 0% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and the survival was significantly better than in the control group (P &lt; 0.025) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparing separately each FAB subgroup gave statistical evidence that the treatment prolonged the survival in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> subgroup only (P &lt; 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>The median duration of response was 15 months and the survival in responders was statistically better than in non-responders (P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> has been the most important side effect, however, no <z:hpo ids='HP_0011420'>death</z:hpo> related to the treatment was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Our study suggests that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, who are not suitable candidates for aggressive chemotherapy, could benefit from our treatment schedule </plain></SENT>
<SENT sid="9" pm="."><plain>The long duration of therapy seems to be of value for patients achieving a response in order to prolong the survival </plain></SENT>
<SENT sid="10" pm="."><plain>The toxicity is acceptable and the therapy can be given on an outpatient basis </plain></SENT>
</text></document>